Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.

about

Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms.Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update.

P2860

Q38978004-66DB56D0-96D3-418B-ABBE-6C7498103C80 Q49993294-C8771970-0E60-4E41-B063-B006A5799CF3

P2860

Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.

Item

http://www.wikidata.org/entity/Q38802249

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.

@en

type

Item

label

Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.

@en

prefLabel

Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.

@en

P1476

Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.

@en

P2093

Daniel Egan

http://www.w3.org/2001/XMLSchema#string

Jerald Radich

http://www.w3.org/2001/XMLSchema#string

P2860

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Identification and correction of systematic error in high-throughput sequence data

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Performance comparison of benchtop high-throughput sequencing platforms.

Detection of ultra-rare mutations by next-generation sequencing.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

P304

742-746

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24381

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27059166

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.

about

P2860

P2860

Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921